Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eikon Therapeutics, Inc. - Common Stock (NQ:EIKN)

7.290 -0.250 (-3.32%)
Delayed Quote Updated: 12:08 PM EDT, Oct 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Eikon Therapeutics, Inc. - Common Stock

News headline image
Eikon Therapeutics Submits IND for Novel Androgen Receptor Antagonist EIK1006 in Prostate Cancer
Internally-derived candidate targets wild-type androgen receptor and clinically relevant variants implicated in resistance to conventional prostate cancer therapies 
From Eikon Therapeutics, Inc.
Via GlobeNewswire
News headline image
Eikon Therapeutics Appoints Ching-Pin Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer
From Eikon Therapeutics, Inc.
Via GlobeNewswire
News headline image
Eikon Therapeutics to Participate in Investor Conferences in September 2026
From Eikon Therapeutics, Inc.
Via GlobeNewswire
News headline image
Eikon Therapeutics to Participate in KOL Event on Therapeutic Use of PARP Inhibitors in Oncology Hosted by Cantor Fitzgerald
Event and Webcast to be held August 20th, 2026, 9:00 AM ET 
From Eikon Therapeutics, Inc.
Via GlobeNewswire
News headline image
Eikon Therapeutics Reports Second Quarter 2026 Financial Results and Provides Clinical Updates
From Eikon Therapeutics, Inc.
Via GlobeNewswire
News headline image
Eikon Therapeutics Announces Dose Selection for TeLuRide-006, an Ongoing Adaptive Phase 2/3 Trial of EIK1001 in Advanced Melanoma
From Eikon Therapeutics, Inc.
Via GlobeNewswire
News headline image
Eikon Therapeutics Appoints Johnny Bennett, Ph.D. to its Scientific Advisory Board
Experienced Merck researcher will expand the Board’s drug discovery expertise 
From Eikon Therapeutics, Inc.
Via GlobeNewswire
News headline image
Eikon Therapeutics Announces First Patient Dosed in TeLuRide-008, a Registrational Phase 2/3 Trial of EIK1001 in Non-Small Cell Lung Cancer
From Eikon Therapeutics, Inc.
Via GlobeNewswire
News headline image
Eikon Therapeutics Announces Seven Abstracts Accepted for Presentation at the 2026 European Society of Medical Oncology (ESMO) Congress
From Eikon Therapeutics, Inc.
Via GlobeNewswire
News headline image
Eikon Therapeutics to Join the Russell 3000® Index
Addition reflects Eikon's progress as a publicly traded company and increasing visibility within the investment community 
From Eikon Therapeutics, Inc.
Via GlobeNewswire
News headline image
Eikon Therapeutics Announces the Appointment of Ma. Fatima D. Francisco to its Board of Directors
From Eikon Therapeutics, Inc.
Via GlobeNewswire
News headline image
Eikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical Oncology
From Eikon Therapeutics, Inc.
Via GlobeNewswire
News headline image
Eikon Therapeutics Announces Availability of Six Abstracts for Presentation at the 2026 Annual Meeting of the American Society of Clinical Oncology
From Eikon Therapeutics, Inc.
Via GlobeNewswire
News headline image
Eikon Therapeutics Reports First Quarter 2026 Financial Results and Provides Clinical Updates
From Eikon Therapeutics, Inc.
Via GlobeNewswire
News headline image
Eikon Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Clinical and Corporate Updates
From Eikon Therapeutics, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.